Neurocrine Biosciences, Inc. (NASDAQ: NBIX) presented two-year data for CRENESSITY (crinecerfont) at the Endocrine Society's ENDO 2026 meeting in Chicago, showing sustained improvements in cardiometabolic outcomes for adults with classic congenital adrenal hyperplasia.

The Phase 3 CAHtalyst Adult study data included 182 participants who completed the initial 24-week double-blind period and continued treatment in an open-label extension. Results showed sustained reductions in glucocorticoid doses of 38% at 24 months, alongside improvements in body weight and insulin resistance measures.

Among participants who were overweight or obese at baseline, 37% achieved greater than 5% reduction in body weight at two years. Of those with insulin resistance at baseline, 43% were no longer insulin resistant at two years. Mean body mass index decreased by 0.9 kg/m² and mean insulin resistance scores improved by 1.7 points from baseline.

Bone health outcomes showed favorable trends, with bone mineral density scores improving over time, particularly in the lumbar spine. All bone turnover markers increased from baseline to 12 months, potentially reflecting recovery from glucocorticoid suppression.

A cross-sectional survey of 48 U.S. adult participants indicated 96% were moderately or very satisfied with CRENESSITY treatment. The majority reported having more hope for their future with classic congenital adrenal hyperplasia and feeling more in control of their condition.

CRENESSITY was generally well tolerated through two years of treatment with no new safety signals observed during long-term follow-up, according to the company's press release statement.

The drug received FDA approval in December 2024 for use with glucocorticoids to control androgen levels in adults and children four years and older with classic congenital adrenal hyperplasia.